Key Details
Price
$19.47Annual ROE
-51.52%Beta
1.93Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a.
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
NovoCure (NVCR) reported a quarterly loss of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.43. This is an improvement from the loss of $0.50 per share reported a year ago.
FAQ
- What is the primary business of NovoCure Limited?
- What is the ticker symbol for NovoCure Limited?
- Does NovoCure Limited pay dividends?
- What sector is NovoCure Limited in?
- What industry is NovoCure Limited in?
- What country is NovoCure Limited based in?
- When did NovoCure Limited go public?
- Is NovoCure Limited in the S&P 500?
- Is NovoCure Limited in the NASDAQ 100?
- Is NovoCure Limited in the Dow Jones?
- When was NovoCure Limited's last earnings report?
- When does NovoCure Limited report earnings?
- Should I buy NovoCure Limited stock now?